Further, we compared the expression levels of the immune checkpoints and found that low-risk BRCA patients have higher CD274 (Fig. 5B), PDCD1 (Fig. 5C), and CTLA4 (Fig. 5D) expression level. This evidence concerns the gene CD274 and invasive breast carcinoma.